Riccardo Rinaldi, F. Spione, Filippo Maria Verardi, Pablo Vidal Calés, V. Arévalos, R. Gabani, Daniel Cánovas, Montserrat Gutiérrez, Montserrat Pardo, Rosa Domínguez, Luis Pintor, Xavier Torres, X. Freixa, A. Regueiro, Omar Abdul-Jawad Altisent, Manel Sabaté, and, Salvatore Brugaletta
{"title":"Angina or ischemia with no obstructed coronary arteries: a specific diagnostic and therapeutic protocol","authors":"Riccardo Rinaldi, F. Spione, Filippo Maria Verardi, Pablo Vidal Calés, V. Arévalos, R. Gabani, Daniel Cánovas, Montserrat Gutiérrez, Montserrat Pardo, Rosa Domínguez, Luis Pintor, Xavier Torres, X. Freixa, A. Regueiro, Omar Abdul-Jawad Altisent, Manel Sabaté, and, Salvatore Brugaletta","doi":"10.24875/recice.m23000418","DOIUrl":null,"url":null,"abstract":"Introduction and objectives : A systematic approach to patients with angina with no obstructed coronary arteries (ANOCA) or ischemia with no obstructed coronary arteries (INOCA) patients is not routinely implemented. Methods: All consecutive patients diagnosed with ANOCA/INOCA were referred to a designated outpatient clinic for a screening visit to assess their eligibility for a NOCA program. If eligible, patients underwent scheduled coronary angiograms with coronary function testing and intracoronary acetylcholine provocation testing. Medical therapy was optimized accordingly. All patients were then followed up at 1, 3, 6, and 12 months. Baseline and 3-month follow-up assessments included the Seattle Angina Questionnaire (SAQ) and EuroQol-5D questionnaire. Results: Of 77 patients screened, 23 (29.9%) were excluded and 54 (70.1%) were included (29 [53.7%] with INOCA and 25 [46.3%] with ANOCA). Microvascular angina was diagnosed in 19 (35.2%) patients, vasospastic angina in 12 (22.2%), both microvascular angina and vasospastic angina in 18 (33.3%), and noncoronary chest pain in 5 (9.3%). There was a notable increase in the use of beta-blockers, calcium channel blockers and nitrates. Complications occurred in 3 (5.5%) patients. Compared with baseline, there was no difference in the mean EQ-5D score at the 3-month follow-up, but there was a significant improvement in the SAQ score related to physical limitations, angina stability, and disease perception, with no differences in angina frequency or treatment satisfaction. No events were recorded at the 1-year follow-up. Conclusions: A specific diagnostic and therapeutic protocol can be easily and safely implemented in routine clinical practice, leading to improvement in patients’ quality of life.","PeriodicalId":509332,"journal":{"name":"REC: interventional cardiology (English Edition)","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"REC: interventional cardiology (English Edition)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.24875/recice.m23000418","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction and objectives : A systematic approach to patients with angina with no obstructed coronary arteries (ANOCA) or ischemia with no obstructed coronary arteries (INOCA) patients is not routinely implemented. Methods: All consecutive patients diagnosed with ANOCA/INOCA were referred to a designated outpatient clinic for a screening visit to assess their eligibility for a NOCA program. If eligible, patients underwent scheduled coronary angiograms with coronary function testing and intracoronary acetylcholine provocation testing. Medical therapy was optimized accordingly. All patients were then followed up at 1, 3, 6, and 12 months. Baseline and 3-month follow-up assessments included the Seattle Angina Questionnaire (SAQ) and EuroQol-5D questionnaire. Results: Of 77 patients screened, 23 (29.9%) were excluded and 54 (70.1%) were included (29 [53.7%] with INOCA and 25 [46.3%] with ANOCA). Microvascular angina was diagnosed in 19 (35.2%) patients, vasospastic angina in 12 (22.2%), both microvascular angina and vasospastic angina in 18 (33.3%), and noncoronary chest pain in 5 (9.3%). There was a notable increase in the use of beta-blockers, calcium channel blockers and nitrates. Complications occurred in 3 (5.5%) patients. Compared with baseline, there was no difference in the mean EQ-5D score at the 3-month follow-up, but there was a significant improvement in the SAQ score related to physical limitations, angina stability, and disease perception, with no differences in angina frequency or treatment satisfaction. No events were recorded at the 1-year follow-up. Conclusions: A specific diagnostic and therapeutic protocol can be easily and safely implemented in routine clinical practice, leading to improvement in patients’ quality of life.